Corsair’s treprostinil transdermal patch for pulmonary arterial hypertension (PAH) moves closer to clinical development, Biospace, November 10, 2026

Corsair Pharma, a private company in California, had a positive pre-investigational new drug meeting with the United States Food and Drug Administration (FDA) about its once-daily treprostinil patch (TRX-248 Transdermal System) for pulmonary arterial hypertension (PAH). The Food and Drug Administration supported the company’s plan to seek approval through a shorter regulatory route (the 505(b)(2) […]

Corsair’s treprostinil transdermal patch for pulmonary arterial hypertension (PAH) moves closer to clinical development, Biospace, November 10, 2026 Read Post »

United Therapeutics Corporation announces the U.S. Food and Drug Administration (FDA) Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost Soft Mist Inhaler (SMI) in pulmonary arterial hypertension (PAH)

On October 28, 2026, United Therapeutics Corporation announced that the U.S. Food and Drug Administration (FDA) granted clearance under its Investigational New Drug (IND) application to proceed with a clinical trial of Treprostinil-Iloprost soft mist inhaler (SMI) in pulmonary arterial hypertension. If successful this would be the first use-as-needed prostacyclin combination inhaled therapy for pulmonary

United Therapeutics Corporation announces the U.S. Food and Drug Administration (FDA) Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost Soft Mist Inhaler (SMI) in pulmonary arterial hypertension (PAH) Read Post »

Lung transplantation for severe pulmonary arterial hypertension (PAH) – How far can we go? Pro-lung transplantation, Journal of Heart and Lung Transplantation (JHLT) Open, November 2026

The authors of an article published in Journal of Heart and Lung Transplantation (JHLT) Open in November 2026 explain that in the early days, heart-lung transplantation was the standard for pulmonary arterial hypertension (PAH), because doctors believed the heart was too damaged to recover. Since the 1990s, the approach has shifted to transplanting both lungs

Lung transplantation for severe pulmonary arterial hypertension (PAH) – How far can we go? Pro-lung transplantation, Journal of Heart and Lung Transplantation (JHLT) Open, November 2026 Read Post »

Inhaled nanogels ameliorate vascular remodeling in pulmonary arterial hypertension (PAH) via normalization of endothelia – smooth muscle cell crosstalk, Bioactive Materials, March 2027 edition

According to the authors of an article published in “Bioactive Materials”, maintaining appropriate vascular nitric oxide (NO) levels in pulmonary arteries is very important for the alleviation of pulmonary arterial hypertension (PAH). They have developed inhalable, reactive oxygen species (ROS) – responsive, zwitterionic nanogels (NGs) containing arginine pendants as nitric oxide (NO) precursors and encapsulating

Inhaled nanogels ameliorate vascular remodeling in pulmonary arterial hypertension (PAH) via normalization of endothelia – smooth muscle cell crosstalk, Bioactive Materials, March 2027 edition Read Post »

The connection between Systemic Hypertension (SHT) and Pulmonary Hypertension (PH), JAMA Cardiology, October 30, 2026

A multicenter study analyzed data from the Pulmonary Vascular Research Institute (PVRI) GoDeep registry of 12,771 patients in pulmonary hypertension (PH) World Health Organisation (WHO) groups 1-5 and all age categories. The study found that: Clinical relevance: In pulmonary hypertension patients falling systemic blood pressure may be an important warning sign of haemodynamic deterioration and

The connection between Systemic Hypertension (SHT) and Pulmonary Hypertension (PH), JAMA Cardiology, October 30, 2026 Read Post »

The role of Treprostinil Inhalation Powder among inhaled formulations for Pulmonary Arterial Hypertension (PAH), The Annals of Pharmacotherapy, October 30, 2026

A review published in The Annals of Pharmacotherapy looks at Yutrepia a dry powder form of inhaled treprostinil, and how it compares with the other inhaled treprostinil options for pulmonary arterial hypertension (PAH), in particular Tyvaso DPI. The authors searched the medical literature up to September 2026 and included twelve studies covering efficacy, safety, how

The role of Treprostinil Inhalation Powder among inhaled formulations for Pulmonary Arterial Hypertension (PAH), The Annals of Pharmacotherapy, October 30, 2026 Read Post »

Study uncovers why pulmonary hypertension (PH) patients report symptoms of cognitive decline, Journal of Clinical Investigation, November 2, 2026

A new study by researchers at the University of Pittsburgh Medical Center, USA, suggests that pulmonary hypertension (PH) can affect not only the heart and lungs but also the brain, potentially explaining why some patients experience memory problems, difficulty concentrating and impaired thinking. Researchers found that inflammation linked to a genetic factor called NCOA7 may

Study uncovers why pulmonary hypertension (PH) patients report symptoms of cognitive decline, Journal of Clinical Investigation, November 2, 2026 Read Post »

The Canadian Pulmonary Hypertension (PHA Canada)’s campaign for November, Pulmonary Hypertension Awareness Month, is called “Make the connection”

“Make the Connection“, is the theme of the Canadian Pulmonary Hypertension (PHA Canada)’s campaign for November awareness month. Ths campaign is about helping more healthcare professionals recognize pulmonary hypertension (PH) and connect patients and caregivers with information, resources, and support. Read more about how to join the campaign at this link The celebrations for November

The Canadian Pulmonary Hypertension (PHA Canada)’s campaign for November, Pulmonary Hypertension Awareness Month, is called “Make the connection” Read Post »

The US Pulmonary Hypertension Association (PHA) launches its “Living under pressure” campaign for November, Pulmonary Hypertension Awareness month

During Pulmonary Hypertension Awareness Month, the ‘Living Under Pressure’ campaign raises awareness of the medical realities of pulmonary hypertension and the everyday pressures that accompany living with a serious condition. Read more about how to contribute at this link on the Pulmonary Hypertension Association’s website

The US Pulmonary Hypertension Association (PHA) launches its “Living under pressure” campaign for November, Pulmonary Hypertension Awareness month Read Post »

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – October 2026

October was a busy month for the pulmonary hypertension community. The Alliance for Pulmonary Hypertension added five new PEP Talks and, together with the European Pulmonary Fibrosis Federation (EU-PFF), held a webinar on pulmonary hypertension associated with interstitial lung disease. On the treatment front Gossamer Bio has submitted a New Drug Application (NDA) for seralutinib

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – October 2026 Read Post »

Extension Studies in Treprostinil Palmitil Inhalation Powder (TPIP) Show Promise in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), American Journal of Managed Care, October 20, 2026

At the annual meeting of the American College of Chest Physicians, October 18-21. 2026, Insmed presented new data on treprostinil palmitil inhalation powder. This is an investigational inhaled prostacyclin-pathway drug that is released slowly in the lungs, so a single daily dose works for 24 hours. Current inhaled treprostinil needs four sessions a day. In

Extension Studies in Treprostinil Palmitil Inhalation Powder (TPIP) Show Promise in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), American Journal of Managed Care, October 20, 2026 Read Post »

Five new PEP Talks now online in the dedicated section of this website

Have you watched our latest PEP Talks? In the five most recent videos: 🔹 Aygün Mengelli Tomur (Turkey) reflects on life after lung transplantation, gratitude to her donor, and the importance of organ donation. 🔹 Jolie Lizana (USA) draws on her experience as a person living with pulmonary arterial hypertension, her healthcare background, and her

Five new PEP Talks now online in the dedicated section of this website Read Post »

Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026

Quince Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, has announced that it has changed its name to IRulya Therapeutics Inc. IRulya will be focused on advancing LAM-001, an investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases. LAM-001 is a

Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026 Read Post »

Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026

An article published recently on the Expert Review of Medicine reviews the epidemiology of obesity and its impact on pulmonary arterial hypertension. The typical patient has changed over the years from a young, lean, woman to an older person with other conditions such as obesity, diabetes or heart disease. Obesity is now one of the

Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026 Read Post »

First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026

Researchers from a tertiary pulmonary hypertension expert center in Abu Dhabi, United Arab Emirates, conducted a retrospective single-center cohort study (PH RISE-ME) evaluating the real-world effectiveness and safety of sotatercept in adults with pulmonary arterial hypertension already on optimised background therapy. The findings reveal that adding sotatercept In this cohort was associated with improved right-heart

First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026 Read Post »

Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal, October 23, 2026

A retrospective study by researchers in Turkey looked at a simple index based on three routine blood measurements: platelets, albumin and bilirubin. The “PALBI” index reflects how pulmonary hypertension affects both the heart and the liver. Researchers applied it to 3,432 people, including 1,520 patients with pulmonary hypertension identified by echocardiography. The final cohort comprised

Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal, October 23, 2026 Read Post »

United Therapeutics (UTHR) Opens Xeno Organ Production Sites In Houston And Stewartville, Simply Wall Street, October 24, 2026

With its new facilities in Houston and Stewartville, United Therapeutics is turning its organ programme from an idea into a concrete part of the business. Rather than relying only on its lung medicines to grow, the company is now investing in physical sites to build a second line of business: producing organs for transplant alongside

United Therapeutics (UTHR) Opens Xeno Organ Production Sites In Houston And Stewartville, Simply Wall Street, October 24, 2026 Read Post »

TRANSLATE »
Scroll to Top